LSV Asset Management Has $338.06 Million Stake in Incyte Corporation $INCY

LSV Asset Management boosted its position in shares of Incyte Corporation (NASDAQ:INCY) by 3.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,986,097 shares of the biopharmaceutical company’s stock after buying an additional 124,266 shares during the quarter. LSV Asset Management’s holdings in Incyte were worth $338,061,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership lifted its position in shares of Incyte by 701.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock valued at $185,957,000 after buying an additional 2,390,084 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Incyte by 21.8% during the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after acquiring an additional 1,465,286 shares during the last quarter. Norges Bank bought a new stake in Incyte in the 2nd quarter valued at $96,776,000. Pacer Advisors Inc. lifted its holdings in Incyte by 8,091.6% during the 3rd quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after purchasing an additional 1,233,399 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Incyte during the second quarter worth $82,485,000. Institutional investors own 96.97% of the company’s stock.

Wall Street Analyst Weigh In

INCY has been the topic of several research analyst reports. Guggenheim raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Monday, November 3rd. Piper Sandler raised their price objective on shares of Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Stifel Nicolaus upped their target price on Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $135.00 target price on shares of Incyte in a research note on Wednesday. Finally, Royal Bank Of Canada reduced their price target on Incyte from $95.00 to $92.00 and set a “sector perform” rating for the company in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $103.94.

Incyte Stock Down 1.2%

NASDAQ INCY opened at $98.84 on Thursday. The company has a market cap of $19.40 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 0.60 and a beta of 0.82. Incyte Corporation has a 1-year low of $53.56 and a 1-year high of $112.29. The company has a current ratio of 3.23, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $101.75 and a 200-day moving average of $93.81.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.Incyte’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business earned $1.43 EPS. On average, equities research analysts expect that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the transaction, the executive vice president directly owned 63,129 shares of the company’s stock, valued at $6,471,353.79. This trade represents a 24.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Tray sold 2,774 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the transaction, the insider owned 22,973 shares of the company’s stock, valued at $2,297,300. The trade was a 10.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,225 shares of company stock worth $9,519,745 over the last three months. Company insiders own 17.80% of the company’s stock.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management laid out a 10–13% revenue growth target for 2026 and emphasized pipeline expansion and upcoming product launches, which supports medium‑term revenue upside if clinical readouts and launches progress as planned. Article Title
• Positive Sentiment: Q4 product sales topped expectations (Jakafi and Opzelura contributed to a ~28% revenue jump), showing demand strength that supports near-term cash flow. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy and $135 target (and other bullish research notes highlighted long‑term revenue durability), which could attract buyers looking past the guidance miss. Article Title
• Neutral Sentiment: Company provided an earnings‑call transcript and slide deck; management framed growth “beyond Jakafi,” useful for investors parsing product mix and timing of launches. Article Title
• Neutral Sentiment: Incyte completed a real‑estate sale (Wilmington Bracebridge towers), a non‑core cash/asset move that modestly improves balance sheet flexibility but is unlikely to materially alter operating outlook. Article Title
• Neutral Sentiment: Analyst coverage is mixed/pragmatic — some trims to targets but others reaffirm buys; expect continued analyst debate while Jakafi patent timing and Opzelura trajectory become clearer. Article Title
• Negative Sentiment: EPS missed estimates (Q4 EPS $1.80 vs. ~$1.96 expected) and management issued a softer 2026 revenue forecast; that guidance miss is the primary driver of today’s pullback. Article Title
• Negative Sentiment: Royal Bank of Canada lowered its price target (to $92) and commentary flagged downside vs. current levels, which may weigh on sentiment until guidance clarity improves. Article Title
• Negative Sentiment: Regulatory risk: emerging “Most Favored Nation” drug‑pricing policies and looming Jakafi patent expiry remain material downside risks to margin and revenue durability. Article Title

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.